Skip to navigation Skip to content

Clinical Trial: Ofatumumab

Share

Details
Type of MS: RRMS|SPMS
Treatment mode of action: To affect immune function
Number of Subjects: 4
Medication: Ofatumumab
Location: Florida
Institutions: ClinCloud LLC
Address: 1640 N. Maitland Ave
Suite 1000
Maitland, FL 32751 Contact Information
Landon Estes
407-636-4031
lestes@Myclincloud.com

Funding:

Novartis

Description

A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient- reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy.

FDA Approved medication (Brand name: KESIMPTA)
Open Label
96 weeks long
Once monthly dose
Self-administered

This site is following COVID-19 guidelines from the CDC, Florida Department of Health, and healthcare advisers.  ClinCloud has taken a series of steps to maintain a level of hygiene and cleanliness for the health of participants and staff.

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.